Respiratory Neoplasms without CC/MCC DRG

DRG 182 encompasses hospital admissions for primary malignant neoplasms of the respiratory system without Complication or Comorbidity or Major Complication or Comorbidity, covering routine surgical or medical care for lung cancer when no additional coded complications exist. This grouping matters for inpatient reimbursement because it sets the prospective payment level under Medicare and hinges on accurate coding of comorbidities to determine appropriate payment tiering.

DRG 182 Overview

DRG 182 covers inpatient admissions for primary malignant respiratory neoplasms without documented Complication or Comorbidity and without Major Complication or Comorbidity. This category typically includes straightforward hospital stays for diagnostic workup, limited surgical resection, or medical management of primary lung cancer when no additional coded complications are present. It matters for Medicare payment because classification into this Diagnosis-Related Group determines the base prospective payment and influences resource allocation for hospitals. Correct coding of comorbidities and complications affects payment tiering between DRG 182 and higher-paying groups.

Perioperative and neoadjuvant therapy trials evaluating timing and sequencing of chemotherapy and/or radiotherapy for patients with resectable respiratory neoplasms. These studies enroll inpatients who are planned for surgical resection or are receiving inpatient perioperative care, comparing outcomes such as tumor downstaging, rates of complete (R0) resection, postoperative complications, and length of stay. Results are directly relevant to providers and payers because optimizing preoperative treatment can reduce operative morbidity, readmissions, and overall inpatient resource utilization tied to this DRG.
Comparative effectiveness studies of inpatient management strategies for complications of respiratory neoplasms, such as hemoptysis control, malignant pleural effusion management, or acute airway obstruction. These studies compare interventions (for example, endobronchial procedures versus chest tube/drain strategies, or different protocols for transfusion and hemostasis) in hospitalized patients to measure short-term outcomes like need for escalation of care, ICU transfer, procedural success, and hospitalization costs. Payers and hospitals benefit from evidence about which approaches shorten length of stay, lower complication and readmission rates, and improve cost-effectiveness for patients classified in this DRG.
Post-discharge and survivorship outcome studies assessing functional recovery, symptom burden, and healthcare utilization after inpatient treatment for respiratory neoplasms without CC/MCC. Cohorts follow patients discharged after surgery or inpatient procedures to evaluate readmission drivers, outpatient therapy adherence, palliative needs, and quality-of-life trajectories over months to years. This research informs discharge planning, transitional care interventions, and reimbursement models by identifying targets to reduce avoidable readmissions and downstream costs for this patient population.

Perioperative and neoadjuvant therapy trials evaluating timing and sequencing of chemotherapy and/or radiotherapy for patients with resectable respiratory neoplasms. These studies enroll inpatients who are planned for surgical resection or are receiving inpatient perioperative care, comparing outcomes such as tumor downstaging, rates of complete (R0) resection, postoperative complications, and length of stay. Results are directly relevant to providers and payers because optimizing preoperative treatment can reduce operative morbidity, readmissions, and overall inpatient resource utilization tied to this DRG.
Comparative effectiveness studies of inpatient management strategies for complications of respiratory neoplasms, such as hemoptysis control, malignant pleural effusion management, or acute airway obstruction. These studies compare interventions (for example, endobronchial procedures versus chest tube/drain strategies, or different protocols for transfusion and hemostasis) in hospitalized patients to measure short-term outcomes like need for escalation of care, ICU transfer, procedural success, and hospitalization costs. Payers and hospitals benefit from evidence about which approaches shorten length of stay, lower complication and readmission rates, and improve cost-effectiveness for patients classified in this DRG.
Post-discharge and survivorship outcome studies assessing functional recovery, symptom burden, and healthcare utilization after inpatient treatment for respiratory neoplasms without CC/MCC. Cohorts follow patients discharged after surgery or inpatient procedures to evaluate readmission drivers, outpatient therapy adherence, palliative needs, and quality-of-life trajectories over months to years. This research informs discharge planning, transitional care interventions, and reimbursement models by identifying targets to reduce avoidable readmissions and downstream costs for this patient population.

OpenPayer

Summary & Overview

Respiratory Neoplasms without CC/MCC: Inpatient Reimbursement Overview

DRG 182 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes